← Eichor
Condition: Transfusion Dependent Anemia Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Transfusion Dependent Anemia

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Study Evaluating the Safety and Efficacy of LentiRed Drug Product in Transfusion-dependent β-Thalassemia [TDT]
EARLY_Phase 1 · 1 location(s) · First Affiliated Hospital of Guangxi Medical University · NCT05762510A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS
Phase 3 · 179 location(s) · Takeda · NCT06499285Long-term Follow-up Study of BRL-101 for TDT
Phase N/A · 7 location(s) · Bioray Laboratories · NCT06298630A Study to Determine the Efficacy and Safety of Luspatercept in Adult Participants and to Evaluate the Safety and Pharma
Phase 2 · 36 location(s) · Bristol-Myers Squibb · NCT05664737A Multiple Ascending Dose Study of 9MW3011 in Patients With Non-transfusion-dependent β-thalassemia
Phase 1 · 2 location(s) · Mabwell (Shanghai) Bioscience Co., Ltd. · NCT06772766Quality of Life-Guided Transfusion in Refractory MDS or AML
NA · 1 location(s) · Centre Hospitalier Universitaire de Nice · NCT07328191Unraveling the Impact of Thalidomide at Diverse Doses in Transfusion Dependent Beta Thalassemia
Phase 2 · 1 location(s) · National Institute of Blood and Marrow Transplant (NIBMT), P · NCT06490627Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Myelofibrosis
Phase 2 · 33 location(s) · GlaxoSmithKline · NCT06517875Evaluating Safety and Efficacy of Lentiviral-transduced CD34+ HSCs in Β-thalassaemia Patients.
Phase 1 · 3 location(s) · Shenzhen Hemogen · NCT06655662Efficacy and Safety of Luspatercept for the Treatment of Anemia Due to MDS With del5q, Refractory/Resistant/Intolerant t
Phase 2 · 23 location(s) · Associazione Qol-one · NCT05924100Safety and Efficacy of the Lentiviral Vector in Gene Therapy of Beta-thalassemia Patients
NA · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT06219239T-Cell Depleted Alternative Donor Bone Marrow Transplant for Sickle Cell Disease (SCD) and Other Anemias
Phase 1/Phase 2 · 1 location(s) · Paul Szabolcs · NCT03653338Tranexamic Acid for Reduction of Transfusion in Abdominal Surgery
Phase 3 · 2 location(s) · Ulrich Ronellenfitsch, MD · NCT06414031Luspatercept + Darbepoetin in MDS
Phase 2 · 3 location(s) · Yale University · NCT07096297Long-term Follow-up Study of BHC001 for TDT
Phase N/A · 2 location(s) · Bioray Laboratories · NCT06314529Assessing the Safety, Tolerability, and Efficacy of APR-2020 in Pediatric and Adolescent Subjects With RPS19 Deficient D
Phase 1 · 2 location(s) · Apriligen, Inc. · NCT07476183A Trial Testing SP-420 in Subjects With Transfusion-dependent β-thalassemia or Low-risk Myelodysplastic Syndromes
Phase 2 · 1 location(s) · Pharmacosmos A/S · NCT05693909Evaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia an
Phase 3 · 6 location(s) · Vertex Pharmaceuticals Incorporated · NCT05477563Allo HSCT for High Risk Hemoglobinopathies
Phase 2 · 1 location(s) · Masonic Cancer Center, University of Minnesota · NCT06872333Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT
Phase 2 · 1 location(s) · Paul Szabolcs · NCT01962415Hematopoietic Stem Cell BCL11A Enhancer Gene Editing for Severe β-Hemoglobinopathies
Phase 1 · 1 location(s) · Daniel Bauer · NCT06647979ALS20-101 Lentiviral Gene Therapy for Beta Thalassemia
Phase 1/Phase 2 · 1 location(s) · Children's Hospital of Philadelphia · NCT06364774
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.